Asia Pacific Erythropoietin Drugs Market Size & Outlook
Asia Pacific erythropoietin drugs market, 2018-2030 (US$M)
Related Markets
Asia Pacific erythropoietin drugs market highlights
- The Asia Pacific erythropoietin drugs market generated a revenue of USD 1,651.9 million in 2023.
- The market is expected to grow at a CAGR of 3% from 2024 to 2030.
- In terms of segment, biosimilars was the largest revenue generating type in 2023.
- Biosimilars is the most lucrative type segment registering the fastest growth during the forecast period.
- Country-wise, India is expected to register the highest CAGR from 2024 to 2030.
Asia Pacific data book summary
| Market revenue in 2023 | USD 1,651.9 million |
| Market revenue in 2030 | USD 2,036.9 million |
| Growth rate | 3% (CAGR from 2023 to 2030) |
| Largest segment | Biosimilars |
| Fastest growing segment | Biosimilars |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Biologics, Biosimilars |
| Key market players worldwide | Johnson & Johnson, Novartis AG ADR, Teva Pharmaceutical Industries Ltd, Amgen Inc, Roche Holding AG ADR, Intapp Inc, Dr Reddy's Laboratories Ltd ADR, LG Chem, Sun Pharmaceutical Industries, Biocon |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.6% of the global erythropoietin drugs market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 2,036.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Erythropoietin Drugs Market Scope
Erythropoietin Drugs Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Asia Pacific erythropoietin drugs market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to erythropoietin drugs market will help companies and investors design strategic landscapes.
Biosimilars was the largest segment with a revenue share of 60.22% in 2023. Horizon Databook has segmented the Asia Pacific erythropoietin drugs market based on biologics, biosimilars covering the revenue growth of each sub-segment from 2018 to 2030.
- Asia Pacific Erythropoietin Drugs Type Outlook (Revenue, USD Million, 2018-2030)
- Biologics
- Biosimilars
- Asia Pacific Erythropoietin Drugs Product Outlook (Revenue, USD Million, 2018-2030)
- Erythropoietin
- Darbepoetin-alfa
- Asia Pacific Erythropoietin Drugs Application Outlook (Revenue, USD Million, 2018-2030)
- Cancer
- Renal Diseases
- Neurology
- Other Applications
Reasons to subscribe to Asia Pacific erythropoietin drugs market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Asia Pacific erythropoietin drugs market databook
-
Our clientele includes a mix of erythropoietin drugs market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific erythropoietin drugs market , including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific erythropoietin drugs market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Asia Pacific erythropoietin drugs market size, by country, 2018-2030 (US$M)
Asia Pacific Erythropoietin Drugs Market Outlook Share, 2023 & 2030 (US$M)
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
